Key statistics
As of last trade, Shanghai Junshi Biosciences Co Ltd (688180:SHH) traded at 30.50, 32.15% above the 52 week low of 23.08 set on Sep 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 31.05 |
---|---|
High | 31.44 |
Low | 30.29 |
Bid | 30.50 |
Offer | 30.51 |
Previous close | 30.86 |
Average volume | 9.57m |
---|---|
Shares outstanding | 985.69m |
Free float | 689.94m |
P/E (TTM) | -- |
Market cap | 26.31bn CNY |
EPS (TTM) | -1.83 CNY |
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Announcements
- Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab
- Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China’s Hong Kong SAR
- Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab
- Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates
- Junshi Biosciences Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma
- Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab
- Junshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma
- Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Advanced TNBC
- Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer
- Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint
More ▼